TrialCancer biology & therapy2016

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Matjaz Zwitter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.